Acino to buy Mepha businesses in Latin America, Asia; Ranbaxy's $500M reserve wipes out Lipitor gains;

@FiercePharma: Actavis CEO says generics biz "as we know it" is doomed as company launches branded pain drug in U.S. Release | Follow @FiercePharma

> Swiss drugmaker Acino plans to buy the Latin American and Asian businesses from Teva Pharmaceutical Industries' ($TEVA) generics unit Mepha, as part of a deal worth €94 million ($122 million). Report

> Analysts say Ranbaxy Laboratories' $500 million reserve for a settlement with the U.S. Justice Department will more than offset the gains from its exclusive launch of generic Lipitor. News

> Transcept Pharmaceuticals won a $10 million milestone payment from Purdue Pharma for the sleep drug Intermezzo's new listing in the FDA Orange Book. Story

> Dental anesthetic maker Novocol Pharmaceutical is spending about $54 million to upgrade a plant in Ontario, Canada. Release

> Indian officials suggest that the country follow the U.S. and EU in sharing manufacturing inspections, in this case with neighboring countries in Asia and Africa. News

> Miami-based Opko Health is buying the Israeli active pharmaceutical ingredients manufacturer FineTech Pharmaceutical; terms weren't disclosed. Article

Biotech News

@FierceBiotech: More than 1/3 of clinical trials conducted by pharma cos. are now being outsourced, says a Kalorama report. Story  | Follow @FierceBiotech

@JohnCFierce: Proposed "model" plan would restrict portions of sensitive studies to "legitimate scientists." Via WSJNews | Follow@JohnCFierce

@RyanMFierce: Seattle's #biotech scene lacked startup activity in '11 but didn't want for M&A action via @ldtimmerman. Article  | Follow @RyanMFierce

> Roche CEO Schwan outlines drug/diagnostic acquisition strategy. News

> Vivus sinks after delivering oral cleft data on obesity drug ingredient. More

Vaccines News

> Pfizer, GSK to provide more discount vaccines for GAVI. Story

> Oxford researchers find malaria vaccine target. Article

Manufacturing News

> FDA cites Akzo for contamination, leaky equipment. News

> Counterfeiter with Chinese connections is busted. Story

> Daiichi grimaces at Ranbaxy, FDA consent decree. Report

> Trout forges ahead on Novartis-MIT continuous processing effort. Article

And Finally... Mutations in a single gene are associated with rare ovarian, uterine and testicular cancers that previously appeared unrelated, researchers found. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.